2025 ACE Report Card on Arthritis Medication Coverage

In this special episode of Arthritis At Home, host Kelly Lendvoy speaks with Cheryl Koehn, President and Founder of Arthritis Consumer Experts, about the release of the 2025 ACE Arthritis Medications Report Card and key changes in this year’s rankings – including new listings and major shifts among provinces. The Report Card is one of the Canadian arthritis community’s most trusted advocacy tools, ranking each provincial, territorial, and federal drug plan on how well they provide reimbursement coverage for arthritis medications – including biologics, biosimilars, and targeted synthetic molecule therapies.Cheryl explains how the Report Card originated and evolved into one of the arthritis community’s most valuable information and advocacy resources and helps people with arthritis understand what treatments are covered where they live, for which diseases and under what criteria. For someone newly diagnosed or changing treatments, this can be incredibly confusing and stressful. The Report Card is designed to make a very complex reimbursement coverage system understandable for people living with arthritis.Kelly and Cheryl also look at how ACE leverages the Report Card in meetings with public drug plan managers and elected officials about what governments can do to ensure medication access is patient-centred, evidence-based, and fair across every province and territory.Click here to see how your provincial, territorial or federal drug plan ranks in terms of providing reimbursement for medications approved for inflammatory arthritis such as rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, lupus and juvenile idiopathic arthritis, and vasculitis as well as osteoporosis.Additional learning resourcesACE Arthritis Medications Report CardACE AdvocacyACE Advocacy Toolkit